Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Frequently asked questions
What sector does Polaryx Therapeutics, Inc. Common Stock (PLYX) operate in?
Polaryx Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Polaryx Therapeutics, Inc. Common Stock (PLYX) current stock price?
As of the latest data, Polaryx Therapeutics, Inc. Common Stock stock price is $1.82, with a previous close of $1.82.
What is Polaryx Therapeutics, Inc. Common Stock (PLYX) current market capitalization?
Polaryx Therapeutics, Inc. Common Stock market cap is approximately 90.72 million.
What is Polaryx Therapeutics, Inc. Common Stock (PLYX) Earnings Per Share (EPS)?
The trailing EPS is -$0.14, and the forward EPS is -$0.29.
What is Polaryx Therapeutics, Inc. Common Stock (PLYX) EBITDA?
Polaryx Therapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.38 million.
Does Polaryx Therapeutics, Inc. Common Stock (PLYX) pay dividends?
No. Polaryx Therapeutics, Inc. Common Stock does not pay a dividend.
When is Polaryx Therapeutics, Inc. Common Stock (PLYX) next earnings report?
Polaryx Therapeutics, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Polaryx Therapeutics, Inc. Common Stock (PLYX) beta (volatility) score?
Polaryx Therapeutics, Inc. Common Stock has a beta of -0.796, indicating lower volatility than the overall market.
